A Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Skyline Therapeutics
Summary
This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.
Eligibility
- Age range
- 50+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: Subjects who only meet all of the following criteria are eligible for this study: * nAMD subjects who have been enrolled in the SKG0106-related study and received SKG0106 injection; * Subjects who voluntarily sign an informed consent form (ICF) and comply with the protocol to complete the study Exclusion Criteria: * Subjects who are judged by the investigator unsuitable for this study
Interventions
- GeneticSKG0106
Non-interventional (observational) study, long-term follow-up safety and efficacy assessments up to 5 years post SKG0106 injection.
Locations (10)
- Ophthalmic Consultants of BostonBoston, Massachusetts
- Retina Consultants of TexasKaty, Texas
- Wagner Macula & Retina CenterNorfolk, Virginia
- The Second Hospital Of Anhui Medical UniversityHefei, Anhui
- Zhejiang Provincial People's HospitalHangzhou, Zhejiang
- Eye Hospital, WMU (Zhejiang Eye Hospital)Wenzhou, Zhejiang